IMW 2021 | The current state of MRD-based therapy for myeloma
Natalie Callander
• 6 Sep 2021
Natalie Callander, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI, talks on the use of measurable residual disease (MRD)-guided therapy for myeloma, discussing its prospects and challenges of its use. Dr Callander explains that patients who achieve sustained MRD-negativity demonstrate improved outcomes; however, it remains to be seen whether MRD-negativity can be sustained longer-term. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
